Tag: clinical trial phases

Patient Recruitment Forecasting Models for Large-Scale Phase 3 Studies: Tools, Strategies, and Risk Control

Posted on digi By digi

Patient Recruitment Forecasting Models for Large-Scale Phase 3 Studies: Tools, Strategies, and Risk Control How to Forecast Patient Recruitment for Global Phase 3 Clinical Trials Why Patient Recruitment Forecasting Matters in Phase 3 Trials Recruiting eligible participants is one of the most critical—and challenging—components of any Phase 3 clinical trial. Delays in recruitment can derail…

Read More “Patient Recruitment Forecasting Models for Large-Scale Phase 3 Studies: Tools, Strategies, and Risk Control” »

Phase 3 (Confirmation and Monitoring)

Use of Patient Registries in Phase 4 Research

Posted on digi By digi

Use of Patient Registries in Phase 4 Research How Patient Registries Support Safety and Outcomes Research in Phase 4 Clinical Trials Introduction Patient registries are organized systems that collect uniform data on a defined population over time. In Phase 4 clinical trials, registries offer unparalleled opportunities to track drug safety, effectiveness, adherence, and real-world outcomes…

Read More “Use of Patient Registries in Phase 4 Research” »

Phase 4 (Post-Marketing Surveillance)

Global Site Feasibility and Selection Strategies for Phase 3 Trials: Ensuring Optimal Trial Execution

Posted on digi By digi

Global Site Feasibility and Selection Strategies for Phase 3 Trials: Ensuring Optimal Trial Execution How to Select the Right Sites Globally for Phase 3 Clinical Trials Why Site Selection Is Critical in Phase 3 Trials Phase 3 clinical trials are large-scale, multi-country studies requiring rapid enrollment, consistent data quality, and regulatory compliance. One of the…

Read More “Global Site Feasibility and Selection Strategies for Phase 3 Trials: Ensuring Optimal Trial Execution” »

Phase 3 (Confirmation and Monitoring)

Using Real-World Evidence (RWE) to Complement Phase 3 Data: Enhancing Clinical Trial Outcomes and Regulatory Value

Posted on digi By digi

Using Real-World Evidence (RWE) to Complement Phase 3 Data: Enhancing Clinical Trial Outcomes and Regulatory Value How Real-World Evidence Can Strengthen Phase 3 Clinical Trial Programs Why Real-World Evidence Matters in the Phase 3 Context Phase 3 clinical trials provide controlled and statistically powered evidence on a drug’s safety and efficacy. However, they are conducted…

Read More “Using Real-World Evidence (RWE) to Complement Phase 3 Data: Enhancing Clinical Trial Outcomes and Regulatory Value” »

Phase 3 (Confirmation and Monitoring)

Real-World Evidence (RWE) Generation from Phase 4 Trials

Posted on digi By digi

Real-World Evidence (RWE) Generation from Phase 4 Trials Generating High-Impact Real-World Evidence from Phase 4 Clinical Trials Introduction Real-World Evidence (RWE) has emerged as a powerful supplement to traditional clinical trial data, especially in Phase 4 trials. Generated from everyday patient experiences and routine care, RWE provides actionable insights that inform healthcare decisions, payer coverage,…

Read More “Real-World Evidence (RWE) Generation from Phase 4 Trials” »

Phase 4 (Post-Marketing Surveillance)

Protocol Amendment Management in Phase 3 Trials: Impact and Risk Control Strategies

Posted on digi By digi

Protocol Amendment Management in Phase 3 Trials: Impact and Risk Control Strategies Managing Protocol Amendments During Phase 3 Trials: A Practical Guide Understanding Protocol Amendments in Phase 3 Protocol amendments are modifications made to a clinical trial protocol after the trial has started. In Phase 3 trials—where regulatory scrutiny, patient numbers, and operational complexity are…

Read More “Protocol Amendment Management in Phase 3 Trials: Impact and Risk Control Strategies” »

Phase 3 (Confirmation and Monitoring)

Post-Marketing Commitments and Post-Authorization Safety Studies (PASS)

Posted on digi By digi

Post-Marketing Commitments and Post-Authorization Safety Studies (PASS) How Phase 4 Commitments and PASS Shape Drug Safety Surveillance Introduction After a medicine enters the market, the need for safety monitoring intensifies—not fades. To ensure ongoing evaluation of benefit-risk balance, regulatory agencies may require pharmaceutical companies to undertake post-marketing commitments (PMCs) and conduct Post-Authorization Safety Studies (PASS)….

Read More “Post-Marketing Commitments and Post-Authorization Safety Studies (PASS)” »

Phase 4 (Post-Marketing Surveillance)

Bridging Studies as a Part of Phase 3 Programs: Regulatory Role, Design, and Global Development

Posted on digi By digi

Bridging Studies as a Part of Phase 3 Programs: Regulatory Role, Design, and Global Development How Bridging Studies Integrate Local Data into Global Phase 3 Clinical Development What Are Bridging Studies in Clinical Research? A bridging study is a supplemental clinical study that provides data on the efficacy, safety, dosage, or pharmacokinetics (PK) of a…

Read More “Bridging Studies as a Part of Phase 3 Programs: Regulatory Role, Design, and Global Development” »

Phase 3 (Confirmation and Monitoring)

Comparative Effectiveness Research in Phase 4: Generating Real-World Value

Posted on digi By digi

Comparative Effectiveness Research in Phase 4: Generating Real-World Value How to Conduct Comparative Effectiveness Research in Phase 4 Clinical Trials Introduction Once a drug is approved and enters the real world, the next question stakeholders ask is: “How does this treatment compare to others already in use?” That’s the domain of Comparative Effectiveness Research (CER),…

Read More “Comparative Effectiveness Research in Phase 4: Generating Real-World Value” »

Phase 4 (Post-Marketing Surveillance)

Pharmacoeconomic Evaluations Embedded in Phase 3 Trials: Building the Value Case Alongside Clinical Evidence

Posted on digi By digi

Pharmacoeconomic Evaluations Embedded in Phase 3 Trials: Building the Value Case Alongside Clinical Evidence How Pharmacoeconomic Studies in Phase 3 Trials Support Drug Value and Market Access What Is Pharmacoeconomic Evaluation? Pharmacoeconomic (PE) evaluation involves the analysis of cost versus benefit of a drug or intervention. These evaluations help determine whether a therapy delivers value…

Read More “Pharmacoeconomic Evaluations Embedded in Phase 3 Trials: Building the Value Case Alongside Clinical Evidence” »

Phase 3 (Confirmation and Monitoring)